SCHEMBL1000673

SCHEMBL1000673

COC1CCCN(S(=O)(=O)c2cccc(C(=O)Nc3ccc(OC(C)C)cc3)c2)C1

nearest known ligand 0.63

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 5/20 0.63
MEN1 O00255 4/20 0.63
L3MBTL1 Q9Y468 1/20 0.56
GAA P10253 3/20 0.54
MAPK1 P28482 2/20 0.54
LMNA P02545 1/20 0.54
ALDH1A1 P00352 5/20 0.53
SMN1; SMN2 Q16637 4/20 0.53
TDP1 Q9NUW8 1/20 0.52
CNR1 P21554 1/20 0.50
NPC1 O15118 2/20 0.49
MAPT P10636 2/20 0.49
KDM4E B2RXH2 1/20 0.49
HTT P42858 1/20 0.49
RAB9A P51151 1/20 0.48
HPGD P15428 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1001582 0.86 KMT2A (0.80) KMT2AMEN1L3MBTL1GAAMAPK1
SCHEMBL1000747 0.83 KMT2A (0.64) KMT2AMEN1L3MBTL1GAAMAPK1
SCHEMBL1001743 0.81 KMT2A (0.56) KMT2AMEN1L3MBTL1GAAMAPK1
SCHEMBL1001481 0.81 KMT2A (0.56) KMT2AMEN1L3MBTL1GAAMAPK1
SCHEMBL1000751 0.81 KMT2A (0.55) KMT2AMEN1L3MBTL1GAAMAPK1
Trifluoroacetic Acid SCHEMBL1003877 0.80 MEN1 (0.46) KMT2AMEN1L3MBTL1GAAMAPK1
Trifluoroacetic Acid SCHEMBL1000490 0.80 MEN1 (0.51) KMT2AMEN1L3MBTL1GAAMAPK1
SCHEMBL1001300 0.80 KMT2A (0.62) KMT2AMEN1L3MBTL1GAAMAPK1
Trifluoroacetic Acid SCHEMBL1002028 0.80 MEN1 (0.48) KMT2AMEN1L3MBTL1LMNAALDH1A1
SCHEMBL1001591 0.79 SMN1; SMN2 (0.57) KMT2AMEN1L3MBTL1GAAMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2280001-B1 LONG-CHAIN FATTY ACID ELONGATION ENZYME INHIBITOR COMPRISING ARYLSULFONYL DERIVATIVE AS ACTIVE INGREDIENT MSD KK (JP) 2014-10-15 EP disclosed
US-8420823-B2 Long-chain fatty acyl elongase inhibitor comprising arylsulfonyl derivative as active ingredient MSD K.K. (JP) 2013-04-16 US disclosed
EP-2280001-A1 LONG-CHAIN FATTY ACID ELONGATION ENZYME INHIBITOR COMPRISING ARYLSULFONYL DERIVATIVE AS ACTIVE INGREDIENT Banyu Pharmaceutical Co., Ltd. (JP) 2011-02-02 EP disclosed
US-20110009622-A1 LONG-CHAIN FATTY ACYL ELONGASE INHIBITOR COMPRISING ARYLSULFONYL DERIVATIVE AS ACTIVE INGREDIENT MSD K.K. (JP) 2011-01-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110009622-A1 LONG-CHAIN FATTY ACYL ELONGASE INHIBITOR COMPRISING ARYLSULFONYL DERIVATIVE AS ACTIVE INGREDIENT ELOVL1, ELOVL6, ELOVL3 KMT2A 473/4885MEN1 4600/4885L3MBTL1 511/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.